TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 6712.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Ever Supreme Bio Technology Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 18.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ever Supreme Bio Technology Co., Ltd’s forward annual dividend is NT$3.33 per share, paid annual. The forward yield is 2.21% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Ever Supreme Bio Technology Co., Ltd’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of NT$1.34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ever Supreme Bio Technology Co., Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$221.00M-7.92% vs estimate |
| Q1 2025 | May 8, 2025 | NT$0.99+53.49% vs estimate | NT$177.92M-7.81% vs estimate |
|---|
| Q4 2024 | Mar 12, 2025 | NT$2.61+58.18% vs estimate | NT$344.00M+19.44% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | NT$0.23+5.41% vs estimate | NT$248.13M+0.05% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$49.85-NT$2.35 (-4.5%)
BIONET Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.75% below the high.
NT$26.40-NT$0.40 (-1.49%)
Taiwan Bio Therapeutics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
NT$58.00+NT$0.60 (+1.05%)
U-Neuron Biomedical Inc’s quoted price sits in the upper half of its reported 52-week range, 17.38% below the high.
NT$20.80-NT$0.30 (-1.42%)
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
